title: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
abstract: BACKGROUND
  Approximately 15% of colorectal cancers develop because of defective function of the DNA mismatch repair (MMR) system. We determined the association of MMR status with colon cancer recurrence and examined the impact of 5-fluorouracil (FU)-based adjuvant therapy on recurrence variables.
  
  
  METHODS
  We included stage II and III colon carcinoma patients (n = 2141) who were treated in randomized trials of 5-FU-based adjuvant therapy. Tumors were analyzed for microsatellite instability by polymerase chain reaction and/or for MMR protein expression by immunohistochemistry to determine deficient MMR (dMMR) or proficient MMR (pMMR) status. Associations of MMR status and/or 5-FU-based treatment with clinicopathologic and recurrence covariates were determined using χ(2) or Fisher Exact or Wilcoxon rank-sum tests. Time to recurrence (TTR), disease-free survival (DFS), and overall survival (OS) were analyzed using univariate and multivariable Cox models, with the latter adjusted for covariates. Tumors showing dMMR were categorized by presumed germline vs sporadic origin and were assessed for their prognostic and predictive impact. All statistical tests were two-sided.
  
  
  RESULTS
  In this study population, dMMR was detected in 344 of 2141 (16.1%) tumors. Compared with pMMR tumors, dMMR was associated with reduced 5-year recurrence rates (33% vs 22%; P < .001), delayed TTR (P < .001), and fewer distant recurrences (22% vs 12%; P < .001). In multivariable models, dMMR was independently associated with delayed TTR (hazard ratio = 0.72, 95% confidence interval = 0.56 to 0.91, P = .005) and improved DFS (P = .035) and OS (P = .031). In stage III cancers, 5-FU-based treatment vs surgery alone or no 5-FU was associated with reduced distant recurrence for dMMR tumors (11% vs 29%; P = .011) and reduced recurrence to all sites for pMMR tumors (P < .001). The dMMR tumors with suspected germline mutations were associated with improved DFS after 5-FU-based treatment compared with sporadic tumors where no benefit was observed (P = .006).
  
  
  CONCLUSIONS
  Patients with dMMR colon cancers have reduced rates of tumor recurrence, delayed TTR, and improved survival rates, compared with pMMR colon cancers. Distant recurrences were reduced by 5-FU-based adjuvant treatment in dMMR stage III tumors, and a subset analysis suggested that any treatment benefit was restricted to suspected germline vs sporadic tumors.
authors: Division of Oncology , Mayo Clinic, Rochester, MN 55905, USA. sinicrope.frank@mayo.edu
authors: Frank A
authors: FA
authors: Sinicrope
authors: Nathan R
authors: NR
authors: Foster
authors: Stephen N
authors: SN
authors: Thibodeau
authors: Silvia
authors: S
authors: Marsoni
authors: Genevieve
authors: G
authors: Monges
authors: Roberto
authors: R
authors: Labianca
authors: George P
authors: GP
authors: Kim
authors: Greg
authors: G
authors: Yothers
authors: Carmen
authors: C
authors: Allegra
authors: Malcolm J
authors: MJ
authors: Moore
authors: Steven
authors: S
authors: Gallinger
authors: Daniel J
authors: DJ
authors: Sargent
references: Cancer Res. 1998 Nov 15;58(22):5248-57
references: 9823339
references: Clin Colorectal Cancer. 2006 Jul;6(2):133-9
references: 16945169
references: Science. 1993 May 7;260(5109):816-9
references: 8484122
references: Clin Cancer Res. 2003 Aug 1;9(8):2898-903
references: 12912934
references: J Clin Oncol. 1995 Sep;13(9):2324-9
references: 7666090
references: N Engl J Med. 2003 Jul 17;349(3):247-57
references: 12867608
references: J Clin Oncol. 2003 Mar 15;21(6):1174-9
references: 12637487
references: Nat Rev Clin Oncol. 2010 Mar;7(3):174-7
references: 20190798
references: Clin Cancer Res. 2008 Jun 1;14(11):3408-15
references: 18519771
references: Cancer. 2000 Nov 15;89(10):2025-37
references: 11066042
references: Clin Cancer Res. 2007 Oct 15;13(20):6093-8
references: 17947473
references: J Clin Oncol. 2005 Jan 20;23(3):609-18
references: 15659508
references: J Clin Oncol. 2010 Jul 10;28(20):3219-26
references: 20498393
references: J Clin Oncol. 1997 Jan;15(1):246-50
references: 8996149
references: Clin Cancer Res. 2005 Dec 1;11(23):8332-40
references: 16322293
references: Gut. 2009 Jan;58(1):90-6
references: 18832519
references: Gastroenterology. 2006 Sep;131(3):729-37
references: 16952542
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Curr Opin Oncol. 2009 Jul;21(4):369-73
references: 19444104
references: Cancer Res. 1996 Nov 1;56(21):4836-40
references: 8895729
references: Int J Colorectal Dis. 2007 Feb;22(2):145-52
references: 16724208
references: J Med Genet. 2004 Sep;41(9):664-8
references: 15342696
references: J Clin Oncol. 2007 Mar 1;25(7):767-72
references: 17228023
references: N Engl J Med. 2001 Apr 19;344(16):1196-206
references: 11309634
references: Arch Surg. 1990 Jul;125(7):897-901
references: 2369315
references: Int J Cancer. 2001 May 20;95(3):162-7
references: 11307149
references: J Clin Oncol. 2006 May 20;24(15):2359-67
references: 16710035
references: Gut. 1998 May;42(5):673-9
references: 9659163
references: Lancet. 1995 Apr 15;345(8955):939-44
references: 7715291
references: J Clin Oncol. 1989 Oct;7(10):1447-56
references: 2778478
references: Lancet. 2000 May 20;355(9217):1745-50
references: 10832824
references: N Engl J Med. 1990 Feb 8;322(6):352-8
references: 2300087
references: J Clin Oncol. 2008 Dec 10;26(35):5783-8
references: 18809606
references: Int J Cancer. 2004 Apr 10;109(3):468-71
references: 14961589
references: Eur J Cancer. 2009 Feb;45(3):365-73
references: 18722765
references: Cancer Res. 2008 Oct 15;68(20):8541-6
references: 18922929
references: Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23
references: 11535541
references: J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303
references: 10433618
references: Gastroenterology. 2011 Apr;140(4):1174-81
references: 21185836
references: Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15
references: 18990764
references: Gastroenterology. 1999 Jun;116(6):1453-6
references: 10348829
references: Int J Cancer. 2009 Mar 1;124(5):x-i
references: 19097168
references: Gastroenterology. 2000 Oct;119(4):921-8
references: 11040179
references: Nature. 1993 Jun 10;363(6429):558-61
references: 8505985